Market Overview

Study Shows Medtronic Insulin Pump Safely Reduces Nocturnal Hypoglycemia


Study results published today in the New England Journal of Medicine and to be presented at the American Diabetes Association (ADA) 73rd Scientific Sessions report that the Threshold Suspend feature of a sensor-augmented insulin pump from Medtronic, Inc. (NYSE: MDT) safely reduces nocturnal hypoglycemia without affecting glycated hemoglobin level (HbA1C). Threshold Suspend - a first-of-its-kind automated insulin pump feature unique to an investigational MiniMed® integrated system - automatically suspends insulin delivery temporarily when sensor glucose values reach a pre-set low level.  It is also an important step toward Medtronic's ultimate goal to develop a fully automated artificial pancreas for people with diabetes. "Hypoglycemia can be catastrophic for people with diabetes, especially at night when patients are likely to be unaware of symptoms because they are asleep," said Richard M. Bergenstal, M.D., executive director of the International Diabetes Center at Park Nicollet Health Services in Minneapolis and past president of medicine and science, American Diabetes Association. "These data are very important because they provide strong evidence that sensor-augmented insulin pump therapy with

See full press release

Posted-In: News Guidance Management


Related Articles (MDT)

View Comments and Join the Discussion!